Mural Oncology Announces Second Quarter Financial Results and Provides Business Update

Mural continues to explore strategic alternatives

Estimates cash and cash equivalents of approximately $43 to $48 million at December 31, 2025, if it has not consummated a transaction or other strategic alternative by year end

Read more at globenewswire.com